Table 3.
Characteristics | 5-Year CSS (%) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Log-rank χ2 test | P | HR (95% CI) | P | ||
Marital status | 55.054 | <0.001 | <0.001 | ||
Unmarried | 39.3 | Reference | |||
Married | 45.7 | 0.794 (0.736–0.857) | |||
Gender | 1.392 | 0.238 | |||
Male | 43.3 | ||||
Female | 42.7 | ||||
Age (years) | 63.046 | <0.001 | <0.001 | ||
<68 | 46.7 | Reference | |||
≥68 | 39.5 | 1.161 (1.075–1.254) | |||
Race | 2.885 | 0.236 | |||
White | 44.1 | ||||
Black | 38.6 | ||||
Othersa | 41.8 | ||||
Insurance | 0.861 | 0.650 | |||
Insured/Medicaid | 42.6 | ||||
Uninsured | 43.6 | ||||
Unknown | 43.6 | ||||
Tumor primary site | 240.334 | <0.001 | 0.014 | ||
Duodenum | 35.6 | Reference | |||
Jejunum | 53.5 | 0.840 (0.741–0.951) | |||
Ileum | 57.0 | 0.851 (0.740–0.978) | |||
Meckel’s diverticulum | 0 | 2.207 (0.913–5.333) | |||
Overlapping lesion of small intestine | 46.5 | 0.897 (0.624–1.287) | |||
Small intestine, NOS | 48.7 | 0.967 (0.853–1.096) | |||
AJCC seventh TNM stage | 689.047 | <0.001 | <0.001 | ||
I | 68.3 | Reference | |||
II | 65.4 | 1.144 (0.880–1.489) | |||
III | 44.5 | 1.887 (1.475–2.413) | |||
IV | 11.1 | 3.191 (2.540–4.008) | |||
Unknown/NA/blank(s) | 42.4 | 1.995 (1.604–2.482) | |||
Grade | 360.890 | <0.001 | <0.001 | ||
Well differentiated | 61.9 | Reference | |||
Moderately differentiated | 51.3 | 1.194 (1.002–1.423) | |||
Poorly differentiated | 38.1 | 1.749 (1.464–2.090) | |||
Undifferentiated/anaplastic | 34.4 | 2.030 (1.387–2.971) | |||
Unknown | 22.0 | 1.290 (1.072–1.552) | |||
Histology | 24.234 | <0.001 | 0.010 | ||
Other adenocarcinoma | 43.3 | Reference | |||
Mucinous adenocarcinoma | 48.6 | 1.070 (0.924–1.240) | |||
Signet ring cell | 24.6 | 1.312 (1.096–1.571) | |||
Surgery | 1,546.559 | <0.001 | <0.001 | ||
Yes | 57.2 | Reference | |||
No | 10.9 | 3.472 (3.138–3.841) | |||
Unknown | 44.7 | 1.321 (0.745–2.341) |
Note:
Including American Indian/AK native and Asian/Pacific Islander (N=448) and unknown race (N=17).
Abbreviations: AJCC, American Joint Committee on Cancer; CSS, cancer-specific survival; NOS, not otherwise specified.